Drug intelligence / Profile preview

AT-587

Development stage: Phase 1
Lead developer: Atea Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AT-587 is an orally bioavailable, direct-acting antiviral (DAA) agent being developed by Atea Pharmaceuticals for the treatment of hepatitis E virus (HEV) infection. It is designed to target single-stranded RNA (ssRNA) viruses, demonstrating high potency against HEV in vitro. The drug aims to address the unmet medical need for effective HEV therapies, particularly for immunocompromised patients who are at risk of chronic infection and liver complications. Atea Pharmaceuticals expects to initiate a Phase 1 clinical program for AT-587 in mid-2026.

Targets

HEV ORF1 (Hepatitis E virus ORF1 polyprotein)

Beyond the preview

Go deeper on AT-587.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-587.

Explore the full profile